Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Total Non-Current Liabilities (2025)

Monte Rosa Therapeutics' Total Non-Current Liabilities history spans 1 years, with the latest figure at $12.1 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities changed N/A year-over-year to $12.1 million; the TTM value through Dec 2025 reached $12.1 million, changed N/A, while the annual FY2025 figure was $12.1 million, N/A changed from the prior year.
  • Total Non-Current Liabilities reached $12.1 million in Q4 2025 per GLUE's latest filing, down from $101.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $101.2 million in Q3 2025 to a low of $12.1 million in Q4 2025.